PT - JOURNAL ARTICLE AU - Lia Boyle AU - Lu Rao AU - Simranpreet Kaur AU - Xiao Fan AU - Caroline Mebane AU - Laura Hamm AU - Andrew Thornton AU - Jared T Ahrendsen AU - Matthew P Anderson AU - John Christodoulou AU - Arne Gennerich AU - Yufeng Shen AU - Wendy K Chung TI - Genotype and defects in microtubule-based motility correlate with clinical severity in <em>KIF1A</em> Associated Neurological Disorder AID - 10.1101/2020.07.27.20162974 DP - 2020 Jan 01 TA - medRxiv PG - 2020.07.27.20162974 4099 - http://medrxiv.org/content/early/2020/07/29/2020.07.27.20162974.short 4100 - http://medrxiv.org/content/early/2020/07/29/2020.07.27.20162974.full AB - KIF1A Associated Neurological Disorder (KAND) encompasses a recently identified group of rare neurodegenerative conditions caused by variants in KIF1A, a member of the kinesin-3 family of microtubule (MT) motor proteins. Here we characterize the natural history of KAND in 117 individuals using a combination of caregiver or self-reported medical history, a standardized measure of adaptive behavior, clinical records, and neuropathology. We developed a heuristic severity score using a weighted sum of common symptoms to assess disease severity. Focusing on 100 individuals, we compared the average clinical severity score for each variant with in silico predictions of deleteriousness and location in the protein. We found increased severity is strongly associated with variants occurring in regions involved with ATP and MT-binding: the P-loop, switch I, and switch II. For a subset of identified variants, we generated recombinant mutant proteins which we used to assess transport in vivo by assessing neurite tip accumulation, and to assess MT binding, motor velocity, and processivity using total internal reflection fluorescence microscopy. We find all patient variants result in defects in transport, and describe three classes of protein dysfunction: reduced MT binding, reduced velocity and processivity, and increased non-motile rigor MT binding. The molecular rigor phenotype is consistently associated with the most severe clinical phenotype, while reduced binding is associated with milder clinical phenotypes. Our findings suggest the clinical phenotypic heterogeneity in KAND likely reflects and parallels diverse molecular phenotypes. We propose a new way to describe KAND subtypes to better capture the breadth of disease severity.Competing Interest StatementThe authors have declared no competing interest.Funding StatementGrant support includes TL1TR001875(LB) R01N114636 (LR AG WKC) KIF1A.org UL1TR001873. Research conducted at the Murdoch Childrens Research Institute was supported by the Victorian Governments Operational Infrastructure Support Program.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Institutional Review Board of Columbia University and informed consent was obtained for all participants.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available from the corresponding author upon reasonable request.